FIGURE 4. Effects of chronic treatment with MnTBAP or rosiglitazone on obese mice.

From the following article:

Reactive oxygen species have a causal role in multiple forms of insulin resistance

Nicholas Houstis, Evan D. Rosen & Eric S. Lander

Nature 440, 944-948(13 April 2006)



a, Effect on body weight. Bars show weights of animals after 12 weeks of treatment with daily subcutaneous injection of MnTBAP or rosiglitazone (Rosiglit.). Animals were treated with 2.5 mg kg-1 (n = 7), 5 mg kg-1 (n = 8) or 10 mg kg-1 (n = 8) MnTBAP, 3 mg kg-1 rosiglitazone (n = 8) or vehicle (phosphate-buffered saline) (n = 8). b, Effect on fed glucose levels. Bars indicate mean fed glucose levels averaged over 18 days during the last eight weeks of treatment. Glucose levels were determined at random times during the day and on random days during this period. c, Effect on insulin sensitivity. Insulin tolerance tests were performed on mice from each treatment group (vehicle, 5 mg kg-1 MnTBAP or rosiglitazone). Lines indicate the time course of glucose levels after subcutaneous injection of human insulin (2 U kg-1). d, Effect on glucose tolerance. Glucose tolerance tests were performed, with lines indicating the time course of glucose excursion following subcutaneous injection of glucose (1 g kg-1) in vehicle-treated, 10 mg kg-1 MnTBAP and rosiglitazone treatment groups. Results are mean plusminus s.e.m. Astersisks indicate P < 0.05 versus vehicle-treated animals (t-test). Glucose and insulin tolerance test data using different dose levels of MnTBAP are provided in Supplementary Information.